Collagen and Joint Pain

What the pooled evidence shows on pain

Joint pain from osteoarthritis is one of the most studied targets for collagen supplementation. A 2025 systematic review and meta-analysis of 11 randomized controlled trials, covering 870 adults with knee osteoarthritis, found that oral collagen-based supplements produced a statistically significant reduction in pain scores compared with placebo. A larger 2024 trial sequential meta-analysis of 35 randomized controlled trials in more than 3,000 osteoarthritis patients similarly reported a small-to-moderate reduction in pain favoring collagen derivatives over control, with the authors noting the analysis had sufficient statistical power to support its conclusions.^{[1], [2]}

Across both analyses, the direction of effect was consistent in favor of collagen for pain, but the magnitude was modest and statistical heterogeneity between individual trials was high. This means the average benefit reported in pooled data may not translate into the same experience for every person who tries collagen for joint pain.^{[1], [2]}

Effects on joint function

Beyond pain, both meta-analyses measured physical function. The 2025 analysis reported a statistically significant improvement in function scores with oral collagen versus placebo in people with knee osteoarthritis, and the 2024 analysis found a small-to-moderate improvement in function that the authors rated as high-certainty evidence. Together, these findings suggest collagen may help with mobility and day-to-day joint use, though the improvements were modest.^{[1], [2]}

Tolerability in trials

The 2024 trial sequential meta-analysis also examined safety and found that oral collagen derivatives did not increase the risk of withdrawal or adverse events compared with control across the included osteoarthritis trials. This supports general tolerability over the typically short study durations, but it does not establish long-term safety, and anyone with a medical condition or who takes medication should consult a clinician before starting a supplement.^[2]

Limitations of the evidence

Both meta-analyses pooled trials that varied in the collagen form used (such as collagen hydrolysate and undenatured type II collagen), dose, and outcome scales, and the 2025 analysis reported high statistical heterogeneity. The reported benefits for pain and function were small-to-moderate on average, so individual responses may differ, and longer and more standardized trials are needed to confirm the size and durability of any effect.^{[1], [2]}

Safety conclusions reflect adverse-event data over relatively short trial periods rather than long-term use, so they should not be read as a guarantee of safety for every person.^[2]